VCM
EWTX icon

Versant Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Versant Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.88K Buy
120
+25
+26% +$862 ﹤0.01% 2436
2026
Q1 		$2.99K Hold
95
– – ﹤0.01% 2496
2025
Q4 		$2.36K Hold
95
– – ﹤0.01% 2422
2025
Q3 		$1.54K Hold
95
– – ﹤0.01% 2451
2025
Q2 		$1.25K Buy
95
+55
+138% +$793 ﹤0.01% 2459
2025
Q1 		$880 Hold
40
– – ﹤0.01% 2374
2024
Q4 		$1.07K Hold
40
– – ﹤0.01% 2182
2024
Q3 		$1.07K Buy
+40
New +$796 ﹤0.01% 1733

Other funds holding EWTX

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CCMG
Connecticut Capital Management Group Milford, Connecticut $124M AUM
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

Versant Capital Management's EWTX Position: Q2 2026 in Review

Versant Capital Management increased its Edgewise Therapeutics (EWTX) stake by 26% in Q2 2026, buying an estimated $862 and bringing the position to 120 shares worth $4.88K. The position accounts for ﹤0.01% of the portfolio, ranked #2436.

Versant Capital Management first reported a position in EWTX in Q3 2024 and has held it in 8 quarters since. 17 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Versant Capital Management held 120 shares of Edgewise Therapeutics worth $4.88K as of Q2 2026.
  • Versant Capital Management bought 25 Edgewise Therapeutics shares in Q2 2026, an estimated $862.
  • Edgewise Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2436 holding.
  • Versant Capital Management first reported a position in Edgewise Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 17 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.